1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

BACKGROUND: Cabotegravir (CAB) and rilpivirine (RPV) are under development as a novel long-acting (LA) regimen for maintenance of HIV virologic suppression. Pooled data from pivotal phase III trials demonstrated noninferiority of CAB + RPV LA given as gluteal intramuscular injections vs current anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Teichner, Paula, Wu, Sterling, Zhang, Feifan, Dorey, David, D’Amico, Ronald, Griffith, Sandy, Sutton, Kenneth, McCoig, Cynthia C, Upadhyay, Ojesh R, Polli, Joseph, Margolis, David, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William, Patel, Parul
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Poster Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777144/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1215
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars